News

Nasdaq3d
Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines
Sanofi SNY announced that it has entered into a definitive agreement to acquire Blueprint Medicines BPMC for a total deal value of up to $9.5 billion. Following the announcement, shares of BPMC ...
Nasdaq4d
Sanofi To Acquire Blueprint Medicines In $9.5 Bln Deal
Sanofi will launch a cash tender offer for Blueprint ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New ...
Nasdaq16d
Sanofi to Acquire Vigil Neuroscience for Up to $10.00 per Share in Cash; Transaction Expected to Enhance Alzheimer’s Drug Development
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY. About Vigil Neuroscience Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common ...
Nasdaq7d
Regeneron and Sanofi Announce Mixed Results from Phase 3 AERIFY Trials for Itepekimab in COPD Patients
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY. Regeneron Forward-Looking Statements and Use of Digital Media This press release includes forward-looking statements that involve risks and ...
Nasdaq10d
Sanofi Buys DR-0201 Myeloid Cell Engager From Dren Bio
Sanofi acquired DR-0201 from a private clinical ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...
Nasdaq15d
Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY. About Vigil NeuroscienceVigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common ...
Nasdaq14d
Sanofi to Join Alzheimer's Space With Vigil Neuroscience Buyout
French pharma giant Sanofi SNY recently announced that it has agreed to acquire Massachusetts-based biotech Vigil Neuroscience VIGL for a total equity value of around $470 million. The acquisition ...
Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout
Sanofi SA (NASDAQ:SNY) on Monday agreed to acquire Blueprint Medicines Corporation (NASDAQ:BPMC). The acquisition includes a ...
Nasdaq3d
Sanofi's Rilzabrutinib Granted FDA's Orphan Drug Designation To Treat Sickle Cell Disease
Sanofi added that the safety and efficacy of ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...
Nasdaq15d
Sanofi To Acquire Vigil Neuroscience With Investigational Alzheimer's Drug VG-3927
On Wednesday, Sanofi closed its trading 0.02% higher at $52.90 on the Nasdaq. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those ...
Nasdaq15d
Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline
while putting sustainability and social responsibility at the center of our ambitions. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY ...
Itepekimab Failure A Setback For Sanofi And Regeneron
Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...